Quinolones: Antibacterial Agents for Respiratory Diseases

Crumplin GC . The mechanism of action of quinolones. In: Percival A , ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:1–14.

Scavone JM , Gleckman RA , Fraser DG . Cinoxacin: Mechanisms of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1982;2:266–271.

Cozzarelli NR . DNA gyrase and supercoiling of DNA. Science 1980;207:953–960.

Gellert M , Mizuuchi K , O'Dea MH , Itoh T , Tomizawa J. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977;74:4772–4776.

Smith JT . Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984;233:299–305.

Klopman G , Macina OT , Levinson ME , Rosenkranz HS . Computer automated structural evaluation of quinolone antibacterial agents. Antimicrob Agents Chemother 1987;31:1831–1840.

Wolfson JJ , Hooper DC . The fluroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985;28:581–586.

Finch RG , Gabbay FJ . The 6-fluoroquinolones' in vitro activity, pharmacokinetic behaviour, and in vivo considerations. In: Percival A , ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:17–27.

Shah PM , Frech K. Overview of clinical experience with the quinolones. In: Percival A , ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:29–42.

Wijnands WJA . The use of enoxacin in respiratory tract infections. In: Percival A , ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:51–57.

Segreti J , Trenholme GM . Antibiotics I. Chest Med 1986;7:393–412.

Neu HC , Reeves DS , eds. Ciprofloxacin. Pharmacokinetics and clinical experience. Eur J Clin Microbiol 1986;5:177–261.

Maesen FPV , Davies BI , Geraedts WH , Baur C. The use of quinolones in respiratory tract infections. Drugs 1987;34(Suppl 1):74–79.

Saito A , Katsu M , Saito A , Soejima R. Ofloxacin in respiratory tract infection: A review of the results of clinical trials in Japan. Drugs 1987;34(Suppl 1):83–89.

Wise R , Leigh DA , eds. Pefloxacin—A laboratory and clinical evaluation of a new quinolone. J Antimicrob Chemother 1986;17(Suppl B):1–118.

Holmes B , Brogden RN , Richards DM . Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1985;30:482–513.

Jensen T , Pedersen SS , Nielsen CH , Hoiby N , Hoch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 1987;20:585–594.

Davis RL , Koup JR , Williams-Warren J , . Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987;31:915–919.

Ravizzola G , Pirali F , Paolucci A , . Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains. J Antimicrob Chemother 1987;20:825–829.

Niki Y , Soejima R , Kawane H , Sumi M , Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest 1987;92:663–669.

Norfloxacin (Noroxin). The Med Letter 1987;29:25–27.